Abstracting and Indexing
Scopus, Chemical Abstracts, CAB abstracts, Hinari, Global Health, EBSCO Publishing's Electronic Databases, Summon by serial solutions, Abstracts on Hygiene and Communicable Diseases, Proquest, Tropical Diseases Bulletin, Open j-Gate, Google Scholar, Science Central, Ulrich's Periodicals Directory, Scimago Journal Ranking, AYUSH Research Portal, Geneva Foundation for Medical Education and Research, ABC Chemistry, Biblioteca, Necker, Academic Journals Database, InfoTrac Custom & Academic Onefile (Gale), Index Medicus for South-East Asia Region (IMSEAR), CNKI scholar.
News & Events
Home > Past Issue
Journal of Applied Pharmaceutical Science Volume: 5, Issue: 2, February, 2015
Non-hematological Adverse Events of Imatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Mehrdad Payandeh, Edris Sadeghi, Masoud Sadeghi
The aim of this study is survey of effects of Imatinib with dose 400 mg per day after 6 months in the patients with CML chronic phase. Between of 2010 - 2014, fifty four patients with high risk CML referred to Taleghani hospital in Kermanshah, Iran. We used the questionnaire about adverse events (AEs) of Imatinib capsule (Cipla manufacture, India) in these patients. For grading AEs, We used Common Terminology Criteria for AEs (CTCAE) manuscript (low AE equals grade 1, 2: high AE equals 3, 4 and grade 5 is optional) that diagram related to them was plotted with Excel 2007 software. 54 patients that referred to hospital, 27 patients were female and 27 patients were male. Mean of age for the patients was 45.7 ± 13.8 years (range, 23 to 78 years). Fatigue, (66.7%), myalgia (61.6%), joint pain (61.6%) and cramp (57.4%) are the most AEs in the patients after treatment of Imatinib. In the future studies we should evaluate non-hematological AEs for Imatinib in a lot of CML patients and apply to CTCAE manuscript exactly.
Keywords: Chronic myeloid leukemia, Fatigue, Imatinib, Myalgia.